Bio-Rad Labs (BIO) Misses Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
Price: $378.09 +0.85%
EPS Growth %: -1.3%
Financial Fact:
Interest expense: 5.63M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -1.3%
Financial Fact:
Interest expense: 5.63M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $3.31, $0.16 worse than the analyst estimate of $3.47. Revenue for the quarter came in at $730.3 million versus the consensus estimate of $747.26 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'
- Intel shares fall as competitor reports record results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
